Paloma Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Paloma Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,060	Closed	-$95.5K	–	263
2024 Q4	$95.5K	Buy	+1,060	New	+$103K	﹤0.01%	260
2023 Q3	–	Sell	-14,928	Closed	-$1.24M	–	950
2023 Q2	$1.24M	Buy	14,928 +1,280	+9%	+$107K	0.04%	320
2023 Q1	$1.04M	Buy	+13,648	New	+$1.13M	0.04%	362
2022 Q1	–	Sell	-22,270	Closed	-$2.49M	–	2298
2021 Q4	$2.49M	Buy	+22,270	New	+$2.69M	0.04%	392
2017 Q2	–	Sell	-42,137	Closed	-$2.92M	–	2474
2017 Q1	$2.92M	Buy	42,137 +7,137	+20%	+$479K	0.04%	562
2016 Q4	$2.07M	Buy	+35,000	New	+$2.16M	0.02%	652

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Paloma Partners's XBI Position: Q1 2025 in Review

Paloma Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 1,060 shares — an estimated $95.5K sold.

Paloma Partners first reported a position in XBI in Q4 2016 and held it in 6 quarters. The position peaked at $2.92M in Q1 2017. 685 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

Paloma Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
Paloma Partners sold 1,060 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $95.5K.
Paloma Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 6 quarters.
Paloma Partners's State Street SPDR S&P Biotech ETF position peaked at $2.92M in Q1 2017.
685 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Paloma Partners's 13F filing for Q1 2025, filed 15 May 2025.